BIOTRONIK Announces Completion of Enrollment in the 4EVER Clinical Study Including Long Lesions in Peripheral Vascular Disease

BUELACH, Switzerland--(BUSINESS WIRE)--BIOTRONIK announced today that the full cohort of 120 patients has been successfully enrolled into the physician-initiated 4EVER clinical study. Follow up is scheduled at 1, 6 and 12 months, with immediate and 6 month results potentially available in January 2012.
MORE ON THIS TOPIC